| Assessment Status | Rapid review complete |
| HTA ID | 22017 |
| Drug | Solriamfetol |
| Brand | Sunosi® |
| Indication | To improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy). |
| Assessment Process | |
| Rapid review commissioned | 28/03/2022 |
| Rapid review completed | 11/04/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that solriamfetol be considered for reimbursement in adult patients with narcolepsy (with or without cataplexy), in accordance with the proposed place in therapy as a second-line treatment*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations – October 2022.
